PTC Therapeutics reported $357.8M in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Cytokinetics USD 47.6M 19M Sep/2026
Daiichi Sankyo JPY 592.49B 17.75B Sep/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Gilead Sciences USD 8.3B 500M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
TG Therapeutics USD 259.94M 19.6M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026
Xencor USD 116.52M 65.3M Sep/2026